Beta-blockers, ACE-I/ARBs, statins

Beta-Blockers - The Heart's Bouncers

• Action: ↓ Heart rate, ↓ contractility, and ↓ blood pressure, leading to decreased myocardial oxygen demand.

• Initiation: Start within 24 hours post-MI if no contraindications.

• Cardioselective (β1 > β2): Metoprolol, Atenolol, Bisoprolol. Preferred to minimize side effects.

• Non-selective (β1 + β2) with α-blocking: Carvedilol, Labetalol.

• Contraindications:

  • Decompensated heart failure (e.g., pulmonary edema)
  • Bradycardia (<60 bpm) or high-degree AV block
  • Hypotension (SBP <100 mmHg)
  • ⚠️ Cocaine-induced MI (risk of unopposed α-adrenergic stimulation).

⭐ Post-MI, beta-blockers are proven to reduce mortality, decrease infarct size, and prevent reinfarction.

ACE-I/ARBs - Remodeling Renegades

• Mechanism: Inhibit the Renin-Angiotensin-Aldosterone System (RAAS) to block Angiotensin II's effects. This ↓ vasoconstriction, ↓ aldosterone secretion, and crucially, prevents adverse cardiac remodeling.
• Clinical Use: Start within 24 hours post-MI in stable patients to reduce mortality and prevent heart failure.
• Key Side Effects:
  • Dry cough (ACE-I only 📌 mnemonic: "ACE gives a Cough")
  • Hyperkalemia
  • Angioedema (rare but serious)
  • ⚠️ Contraindicated in pregnancy & bilateral renal artery stenosis.

⭐ ACE-I/ARBs are proven to decrease mortality and reduce the incidence of subsequent heart failure by mitigating ventricular remodeling, a key long-term complication of MI.

Statins - Plaque's Worst Enemy

• Mechanism: Inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis. This ↑ LDL receptor expression on hepatocytes, leading to ↑ clearance of LDL from circulation.
• Primary Goal: Lower LDL cholesterol (↓ 20-60%). All post-MI patients should be on a high-intensity statin (e.g., Atorvastatin 80 mg, Rosuvastatin 40 mg).
• Key Side Effects:
  • Myopathy/rhabdomyolysis (check CK if symptomatic).
  • Hepatotoxicity (monitor LFTs).

⭐ Pleiotropic Effects: Beyond lipid lowering, statins stabilize plaques, reduce inflammation, and improve endothelial function, contributing significantly to cardiovascular risk reduction.

The MI Triple Threat - Synergistic Super-drugs

Post-MI care combines three drug classes targeting distinct pathways to reduce mortality. This synergistic approach is standard for secondary prevention.

⭐ ACE-inhibitors are critical for preventing adverse ventricular remodeling after an MI, which is a primary driver of post-MI heart failure. This benefit is a class effect.

High‑Yield Points - ⚡ Biggest Takeaways

• Beta-blockers (metoprolol, carvedilol) started within 24 hours post-MI ↓ mortality by decreasing myocardial O₂ demand and risk of arrhythmia.
• ACE inhibitors (e.g., lisinopril) are critical to prevent adverse ventricular remodeling and reduce the risk of subsequent heart failure.
• Use ARBs (e.g., valsartan) as an alternative for patients who are intolerant to ACE inhibitors (e.g., due to cough).
• High-intensity statins (atorvastatin, rosuvastatin) must be started immediately in all patients, regardless of baseline cholesterol, for plaque stabilization.